You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Preclinical development of novel small molecule malaria drugs that overcome drug

    SBC: DESIGNMEDIX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The worldwide health problem created by malaria has been made more difficult by the spread of drug resistant parasites We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine resistant and chloroquine sensitive malaria This project carries on preclinical development of a drug candidate that has been select ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A human cytomegalovirus-based immunotherapy for HIV-1

    SBC: TOMEGAVAX, INC.            Topic: NIAID

    DESCRIPTION The ultimate goal of this project is to develop an immunotherapy for human immunodeficiency virus HIV based on a spread deficient cytomegalovirus CMV derived vaccine expressing andquot tailoredandquot antigens designed for maximal coverage of clade B epitopes In non human primate models rhesus CMV vectored vaccines demonstrated unprecedented protection against highly virulent ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Mobility Life: Monitoring Mobility in Daily Lives of People with Neurological Disease

    SBC: APDM, INC.            Topic: NIA

    Project Summary Falls are the leading cause of injurieshospital visitsnursing home admissionsand reduced quality of life for people with neurological disordersAlthough there is consensus that impaired mobility is the basis for most fallsit is very di cult to evaluate these complex abilities outside a laboratory settingBrief clinical examinations do not accurately re ect dailyfunctional mobility in ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Therapeutic Thrombin Analogs

    SBC: ARONORA INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Project Summary/Abstract Treatment of acute ischemic stroke (AIS) with the thrombolytic/antithrombotic agent tissue plasminogen activator (tPA, Activase(R)) is limited due to the potential for severe hemorrhagic side effects. The first symptoms of acute ischemia to tPA treatment ( time to needle ) can span hours, even in developed urban areas, since an establis ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Therapeutic Thrombin Analogs

    SBC: ARONORA INC            Topic: NHLBI

    DESCRIPTION provided by applicant Project Summary Abstract Treatment of acute ischemic stroke AIS with the thrombolytic antithrombotic agent tissue plasminogen activator tPA Activase is limited due to the potential for severe hemorrhagic side effects The first symptoms of acute ischemia to tPA treatment andquot time to needleandquot can span hours even in developed urban areas since ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A Novel Pharmacological Treatment for Neuropathic Pain

    SBC: Aptinyx Inc            Topic: 105

    PROJECT SUMMARY Neuropathic pain NP conditions affect up to of the population while the annual costs of treatment reach $ billion in the US Pain reduction is more difficult to achieve in NP since the mechanisms involved are not the same as the mechanisms of normal nociceptive pain Current therapeutic approaches offer limited pain relief and frequently produce side effects that outweig ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. HLS- Factor XII Inhibitor for Surface Initiated Thrombosis

    SBC: ARONORA INC            Topic: NHLBI

    DESCRIPTIONprovided by applicantThis Phase I II Fast Track application is being re submitted under the NHLBI Small Business Topics of Special Interest for Fiscal YearHLSCertain life saving interventions such as cardiopulmonary bypassCPBextracorporeal membrane oxygenationECMOor ventricular assist deviceVADpump require the use of high dose heparin to maintain blood flow through the devices and or to ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Colon cancer risk-stratification via optical analysis of rectal ultrastructure

    SBC: American BioOptics, LLC            Topic: NCI

    DESCRIPTIONprovided by applicantThe goal of this small business innovation research grant is to develop and commercialize a highly accurateminimally invasive risk stratification technique for colorectal cancerCRCthat is simple enough to be performed by the primary care provider during an annual physical examAlthough existing guidelines recommend CRC screening for all patients over agertmillion Ame ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. A Proton Radiography System for Optimization of Proton Therapy

    SBC: ProtonVDA LLC            Topic: 102

    Proton radiography produces images of patients in terms of proton stopping power by tracking individual protons before and after the patient and measuring the proton residual range after traversing the patient and would be the most direct method of image guidance for proton radiation therapy Radiation therapy is needed for more than of the million Americans who are annually diagnosed wi ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic Protein C Activator for Myocardial Ischemia

    SBC: ARONORA INC            Topic: NHLBI

    DESCRIPTION provided by applicant Rapidly progressing occlusion of the coronary artery and the subsequent acute myocardial ischemia is the most prevalent primary cause of acute myocardial infarction AMI and death in the United States Early recanalization and antithrombotic therapy promotes reperfusion and improves outcomes when administered before completion of the infarct However most he ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government